File downloaded on 2026-10-31
Source URL: https://medicines.health.europa.eu/veterinary/en/600001882881

Nobivac NXT FeLV (--) - Lyophilisate and solvent for suspension for injection

Authorised

- Feline leukemia virus (strain A/Glasgow-1), gp85 gene encoded by Venezuelan equine encephalitis virus (strain TC-83), self-amplifying RNA, viral particle, replication deficient

Product identification

Medicine name:
Nobivac NXT FeLV (--) - Lyophilisate and solvent for suspension for injection

Active substance:
Feline leukemia virus (strain A/Glasgow-1), gp85 gene encoded by Venezuelan equine encephalitis virus (strain TC-83), self-amplifying RNA, viral particle, replication deficient

Target species:
Cat

Route of administration:
Subcutaneous use

Product details

Active substance and strength:
Feline leukemia virus (strain A/Glasgow-1), gp85 gene encoded by Venezuelan equine encephalitis virus (strain TC-83), self-amplifying RNA, viral particle, replication deficient

Presentation_strength:$10^{6.6}$ – $10^{9.3}$ RP Index:0

Pharmaceutical form:
Lyophilisate and solvent for suspension for injection

Anatomical therapeutic chemical veterinary (ATCvet) codes:
QI06AX

Legal status of supply:
Veterinary medicinal product subject to veterinary prescription

Authorisation status:
Valid

Authorised in:
Austria , Belgium , Bulgaria , Croatia , Cyprus , Czechia , Denmark , Estonia , Finland , France , Germany , Greece , Hungary , Iceland , Ireland , Italy , Latvia , Liechtenstein , Lithuania , Luxembourg , Malta , Netherlands , Norway , Poland , Portugal , Romania , Slovakia , Slovenia , Spain , Sweden , United Kingdom (Northern Ireland)

Package description:
Packaging:Vial (glass), Package_size:Lyophilisate: 5 vials + solvent: 5 vials, Content:Vial of 1 dose + solvent (0.5ml)
Packaging:Vial (glass), Package_size:Lyophilisate: 25 vials + solvent: 25 vials, Content:Vial of 1 dose + solvent (0.5ml)

Additional information

Entitlement type:
Marketing Authorisation

Legal basis of product authorisation:

Full application - new active substance (Article 8 of Regulation (EU) 2019/6)

Marketing authorisation holder:
Intervet International B.V.

Marketing authorisation date:
29/07/2026

Manufacturing sites for batch release:
Intervet International B.V.

Responsible authority:
European Commission

Authorisation number:
This information is not available for this product.

Date of authorisation status change:
29/07/2026

To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet

Documents

Combined File of all Documents

English (PDF)
Published on: 25/08/2026
Download

ema-puar-v6683-nobivacnxtfelv-initial-en.pdf